SELECTION SUMMARY
도입 판단 요약
Monthly Cumulative Percent of Children <8 Months Who Received Nirsevimab by Jurisdiction, United States. Nirsevimab coverage for children 0 to 7 months is assessed through U.S. jurisdictions’ Immunization Information Systems Resources (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group (https://www.cdc.gov/iis/about/).
이 제품의 적합 용도와 제한 조건은 아직 검수하지 않았습니다. 태그와 카테고리는 찾아가는 길이지 적합성 보증이 아닙니다.
